Skip to main content
Ind-Swift Laboratories Ltd. logo

Ind-Swift Laboratories Ltd. — Investor Relations & Filings

Ticker · INDSWFTLAB ISIN · INE915B01019 LEI · 335800ZT8UFD9Y8ZMP56 BSE.NS Manufacturing
Open in API
Filings indexed 816 across all filing types
Latest filing 2024-05-02 Regulatory Filings
Country IN India
Listing BSE.NS INDSWFTLAB

About Ind-Swift Laboratories Ltd.

https://www.indswiftlabs.com

Ind-Swift Laboratories Ltd. is a global manufacturer specializing in Active Pharmaceutical Ingredients (APIs) and Advanced Intermediates. The company focuses on research and development, process chemistry, and large-scale production across diverse therapeutic segments, including macrolide antibiotics, cardiovascular agents, antihistamines, antidiabetics, and antipsychotics. Operating multiple manufacturing facilities that adhere to international regulatory standards such as USFDA, EDQM, and PMDA, the organization provides high-quality chemical entities to the global market. Its core competencies lie in complex chemical synthesis and the development of cost-effective manufacturing processes for generic and specialty drug substances. The company maintains a strong emphasis on quality assurance and regulatory compliance to support its extensive portfolio of products distributed worldwide.

Recent filings

Filing Released Lang Actions
Board Meeting — IND-SWIFT LABORATORIES LIMITED has informed the Exchange about Board Meeting to be held on 13-May-2024 to inter-alia consider and approve the Audited Financial results of the Company…
Regulatory Filings
2024-05-02 English
Board Meeting — Financial Results
Board/Management Information Classification · 95% confidence The document is a notice of a Board meeting scheduled to consider and approve the audited financial results for the quarter and year ended March 31, 2024. It is addressed to stock exchanges and references compliance with SEBI Listing Regulations. The document is short (1910 characters) and serves as an announcement of an upcoming board meeting and financial results approval, not the financial report itself. Therefore, it is an announcement related to corporate governance and board activities, specifically a Board/Management Information filing.
2024-05-02 English
Updates
Regulatory Filings Classification · 95% confidence The document is a compliance letter addressed to stock exchanges (BSE and NSE) regarding Regulation 6(1) and 7(1) of SEBI (LODR) Regulations, 2015. It provides details of the Compliance Officer and Registrar and Transfer Agent (RTA) for the quarter ended March 2024. It also mentions the full repayment of certain debentures and the process of delisting these debentures from BSE. The document is short (2398 characters) and serves as a regulatory compliance update rather than a financial report or detailed announcement. It does not contain financial statements or detailed financial data. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements and compliance documents that do not fit other specific categories.
2024-04-30 English
Updates
Regulatory Filings
2024-04-26 English
Acquisition
Capital/Financing Update Classification · 95% confidence The document is an intimation under Regulation 30 of SEBI Listing Regulations regarding the incorporation of a wholly owned subsidiary in Dubai by Ind-Swift Laboratories Limited. It provides details about the new subsidiary, its business purpose, regulatory approvals, and shareholding. The document is an announcement of a corporate action (incorporation of a subsidiary) and does not contain financial statements, audit information, or detailed financial analysis. It is not a report but a regulatory disclosure about a corporate event. Therefore, it fits best under Capital/Financing Update (CAP) as it relates to changes in the company's capital structure through the creation of a subsidiary.
2024-04-19 English
Updates
Regulatory Filings Classification · 95% confidence The document is a statement submitted to stock exchanges (BSE and NSE) regarding the status of debt securities (Non-Convertible Debentures) for the half year ended March 31, 2024. It references compliance with SEBI circulars and provides detailed data on the issuance, maturity, coupon rate, and repayment status of the NCDs. The document is a regulatory submission of debt securities data rather than a full financial report or earnings release. It is not an announcement of a report publication but a compliance filing with prescribed data. Therefore, it fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2024-04-15 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.